期刊文献+
共找到34,388篇文章
< 1 2 250 >
每页显示 20 50 100
胸腔灌注化疗与胸腔循环热灌注化疗治疗非小细胞肺癌胸腔积液疗效比较 预览
1
作者 刘丽莉 卢英杰 邵文龙 《现代肿瘤医学》 CAS 2019年第11期1895-1899,共5页
目的:探讨与胸腔灌注化疗相比胸腔循环热灌注化疗治疗非小细胞肺癌(NSCLC)胸腔积液的临床疗效,并分析其安全性。方法:选择88例NSCLC合并胸腔积液的患者,随机分为对照组和研究组,每组各44例,对照组应用化疗药物胸腔注入治疗;研究组患者... 目的:探讨与胸腔灌注化疗相比胸腔循环热灌注化疗治疗非小细胞肺癌(NSCLC)胸腔积液的临床疗效,并分析其安全性。方法:选择88例NSCLC合并胸腔积液的患者,随机分为对照组和研究组,每组各44例,对照组应用化疗药物胸腔注入治疗;研究组患者给予胸腔循环热灌注化疗。评估临床疗效、引流管滞留时间、总生存期(OS)、不良反应和毒副反应,并检测两组患者治疗前后外周血C反应蛋白(CRP)、胸腔积液总蛋白定量,应用KPS评分评估患者生存质量。结果:研究组总有效率、OS和KPS评分分别为88.64%(39/44)、(13.45±0.90)个月和(69.82±4.16)分,高于对照组75.00%(33/44)、(10.26±0.84)个月和(67.45±4.06)分,差异具有统计学意义(P<0.05)。研究组引流管滞留时间、血清CRP、胸腔积液总蛋白定量分别为(3.21±0.09)d、(12.53±2.28)mg/L和(22.63±3.48)g/L,低于对照组(4.39±0.11)d、(18.39±2.16)mg/L和(27.49±3.70)g/L,差异具有统计学意义(P<0.05)。研究组患者骨髓抑制、胸痛和胃肠道反应Ⅲ+Ⅳ度发生率分别为15.91%(7/44)、25.00%(11/44)和13.64%(6/44),均低于对照组29.55%(13/44)、36.36%(16/44)和25.00%(11/44),差异具有统计学意义(P<0.05)。研究组患者心衰、肺水肿、气胸、感染总发生率为11.36%(5/44),低于对照组27.27%(12/44),差异具有统计学意义(P<0.05)。结论:胸腔循环热灌注化疗治疗NSCLC胸腔积液临床疗效显著,能够明显缩短引流管滞留时间,降低蛋白量,减弱不良反应和毒副反应,显著提高患者生存期和生存质量。 展开更多
关键词 非小细胞肺癌(NSCLC) 胸腔积液 化疗 胸腔循环热灌注 胸腔灌注化疗
在线阅读 下载PDF
新辅助化疗联合肿瘤细胞减灭术及腹腔热灌注治疗晚期卵巢癌的价值分析
2
作者 周炳秀 杜建英 刘引串 《中国基层医药》 CAS 2019年第15期1858-1861,共4页
目的探讨新辅助化疗联合肿瘤细胞减灭术及腹腔热灌注治疗晚期卵巢癌的效果。方法选择2014年6月至2017年4月在威海市妇幼保健院进行治疗的晚期卵巢癌患者72例为研究对象,按照随机数字表法分为两组,对照组36例,观察组36例。对照组采用新... 目的探讨新辅助化疗联合肿瘤细胞减灭术及腹腔热灌注治疗晚期卵巢癌的效果。方法选择2014年6月至2017年4月在威海市妇幼保健院进行治疗的晚期卵巢癌患者72例为研究对象,按照随机数字表法分为两组,对照组36例,观察组36例。对照组采用新辅助化疗联合肿瘤细胞减灭术治疗,观察组采用新辅助化疗联合肿瘤细胞减灭术及腹腔热灌注治疗。术后化疗3个月后统计疗效。结果观察组手术时间、腹水量、术中出血量均明显少于对照组(均P<0.05);两组手术切口Ⅰ期愈合率、盆腔感染率差异均无统计学意义(均P>0.05)。对照组治疗后缓解率为55.5%(20/36),观察组治疗后缓解率为77.8%(28/36),观察组缓解率明显高于对照组(χ^2=4.92,P<0.05)。所有患者随访1年,对照组复发12例,复发率33.3%;观察组复发8例,复发率22.2%;观察组复发率明显低于对照组(χ^2=5.71,P<0.05)。结论新辅助化疗联合肿瘤细胞减灭术及腹腔热灌注治疗晚期卵巢癌疗效显著,值得临床推广应用。 展开更多
关键词 卵巢肿瘤 化学疗法 辅助 妇科外科手术 化学疗法 局部灌注 透析疗法
Naturally Derived Formulations and Prospects towards Cancer 预览
3
作者 Neha Masarkar Sukhes Mukherjee +1 位作者 Sudhir K. Goel Rajeev Nema 《健康(英文)》 2019年第7期971-997,共27页
Traditional Medicine (TM) and their secondary metabolites are being increasingly recognized as useful complementary treatments toward the cancer. A large number of clinical studies have reported and proven concern of ... Traditional Medicine (TM) and their secondary metabolites are being increasingly recognized as useful complementary treatments toward the cancer. A large number of clinical studies have reported and proven concern of cancer patients. Here we have also reported recent studies on the biochemical and cellular mechanisms of Traditional Medicine (TM). Nowadays, Chemotherapy and surgery are standard methods for treatment of cancer, but still it’s not been fully successful. Some progress has been made in cancer diagnosis and treatment, but high incidence rate of cancer and low survival rate of patient are still being reported worldwide. Since ancient times, a number of traditional medicines known as Ayurveda, Siddha, Unani, Iranian, Chinese, Korean, acupuncture, Muti, Ifa, and African medicine are widely used for therapeutic purposes and are becoming popular as Traditional Medicine (TM). It has been reported that plants synthesize plethora of “secondary metabolites” or “phytochemicals”, proven to possess anti-mutagenic and anti-cancer properties in many research studies. There are many possibilities for further organized research for screening of medicinal plants for their potential and efficacy against chronic diseases such as a cancer and other inflammatory diseases. Therefore, researcher’s interest should be in identification and standardization of new anti-cancer drug with low side effects and greater efficacy, that is easily acceptable in medical community and which may overcome the challenges in present and future cancer therapy. This review explores therapeutic value of certain bio-active principals of plant which could serve as potential pharmacologically active drug for treatment of cancer in future. 展开更多
关键词 Bio-Active Principles CANCER CHEMOTHERAPY PHYTOCHEMICALS SECONDARY METABOLITES
在线阅读 免费下载
胃癌新辅助化疗中DOX与mFOLFOX6方案的疗效和安全性对比分析
4
作者 刘冀衡 曹永清 《中国医师杂志》 CAS 2019年第5期715-718,共4页
目的比较mFOLFOX6(奥沙利铂+氟尿嘧啶)和DOX(多西他赛+奥沙利铂+卡培他滨)两种新辅助化疗方案对局部晚期胃癌患者的疗效及安全性。方法回顾性分析2014年10月至2017年12月入住本院72例确诊为局部晚期胃癌患者,采用新辅助化疗,其中36例采... 目的比较mFOLFOX6(奥沙利铂+氟尿嘧啶)和DOX(多西他赛+奥沙利铂+卡培他滨)两种新辅助化疗方案对局部晚期胃癌患者的疗效及安全性。方法回顾性分析2014年10月至2017年12月入住本院72例确诊为局部晚期胃癌患者,采用新辅助化疗,其中36例采用mFOLFOX6方案,36例采用DOX方案,化疗3个周期后进行临床疗效的判定并分析其不良反应。结果 mFOLFOX6组36例患者中,临床缓解率为27.8%(10/36),疾病控制率为63.9%(23/36);DOX组36例患者中,临床缓解率为36.1%(13/36),疾病控制率为75.0%(27/36),两组的近期临床疗效相比差异无统计学意义(均P>0.05);mFOLFOX6组根治手术R0切除率为66.7%(24/36),DOX组为77.8%(28/36),两组患者的根治手术R0切除率比较差异无统计学意义(P>0.05);DOX方案组呕吐、白细胞减少、血小板减少及手足综合征发生率明显高于mFOLFOX6方案组,差异均有统计学意义(P<0.05)。结论 mFOLFOX6两药方案与DOX三药联合方案在胃癌新辅助化疗中疗效相近,但DOX方案消化道反应及血液学毒性的发生率更高。 展开更多
关键词 胃肿瘤 化学疗法 辅助 抗肿瘤联合化疗方案
Prognostic Factors in Geriatric Patients with Metastatic Colon Cancer 预览
5
作者 Kenji Ina Megumi Kabeya +4 位作者 Shu Yuasa Yuko Kato Satoshi Kayukawa Takae Kataoka Ryuichi Furuta 《癌症治疗(英文)》 2019年第10期779-788,共10页
Backgrounds: Colorectal cancer is an important contributor to cancer morbidity and mortality. Given that many older adult patients often have concomitant diseases and impairments in organ function, they are at increas... Backgrounds: Colorectal cancer is an important contributor to cancer morbidity and mortality. Given that many older adult patients often have concomitant diseases and impairments in organ function, they are at increased risk for chemotherapy toxicity. Therefore, it is important to identify prognostic factors in older patients undergoing chemotherapy. Methods: We performed a retrospective chart review of colorectal cancer patients treated at Nagoya Memorial Hospital between 2012 and 2017 and selected those who received chemotherapy for metastatic colon cancer. Overall survival was calculated from the beginning of chemotherapy until death or the most recent follow-up date. We used the Kaplan-Meier method to plot survival curves and performed a statistical comparison using a log-rank test. In addition, multivariate analysis was performed using stepwise Cox proportional hazards models. Finally, a comprehensive geriatric assessment was conducted for older patients. The chart review was approved by the ethics committee of Nagoya Memorial Hospital. Results: The overall survival of metastatic colon cancer patients was not markedly different between patients aged ≥ 65 years of age (N = 37). Neither lesion site nor the RAS status affected survival, whereas the usage of three kinds of cytotoxic agents prolonged longevity. In a multivariate analysis of patients ≥ 65 years of age, the only independent prognostic factor for survival was the functional capacity, as measured by the Tokyo Metropolitan Institute of Gerontology (TMIG) index of competence. Conclusions: A combination of the comprehensive geriatric assessment and TMIG index was useful for predicting the longevity in patients with metastatic colon cancer ≥ 65 years of age. 展开更多
关键词 METASTATIC COLON Cancer CHEMOTHERAPY COMPREHENSIVE GERIATRIC Assessment TMIG Index of COMPETENCE
在线阅读 免费下载
食管支架介入化疗治疗中晚期食管癌探讨 预览
6
作者 王银昌 《中国卫生标准管理》 2019年第14期50-52,共3页
目的对食管支架介入化疗治疗中晚期食管癌的疗效进行分析探讨。方法将我院2015年1月-2016年12月收治的40例中晚期食管癌患者随机分为两组,对照组20例患者采用常规化疗治疗,观察组20例患者采用食管支架介入化疗治疗,对比两组治疗效果。... 目的对食管支架介入化疗治疗中晚期食管癌的疗效进行分析探讨。方法将我院2015年1月-2016年12月收治的40例中晚期食管癌患者随机分为两组,对照组20例患者采用常规化疗治疗,观察组20例患者采用食管支架介入化疗治疗,对比两组治疗效果。结果观察组营养评分及癌症患者生活质量测评表(QLQ-C30)评分高于对照组,气促指数评分低于对照组(P<0.05)。观察组1年生存率为95.00%,高于对照组的65.00%(P<0.05)。观察组满意度为95.00%,高于对照组的60.00%(P<0.05)。结论对中晚期食管癌患者采用食管支架介入化疗治疗,可有效改善患者营养状况,缓解吞咽困难等临床症状,提高患者的健康与生活质量。 展开更多
关键词 食管癌 食管支架介入 化疗 常规化疗 生存率 吞咽困难
在线阅读 下载PDF
Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy for unresectable sinonasal undifferentiated carcinoma: Two cases of report 预览
7
作者 Sho Watanabe Yoshitaka Honma +13 位作者 Naoya Murakami Hiroshi Igaki Taisuke Mori Hidekazu Hirano Natsuko Okita Hirokazu Shoji Satoru Iwasa Atsuo Takashima Ken Kato Kenya Kobayashi Fumihiko Matsumoto Seiichi Yoshimoto Jun Itami Narikazu Boku 《世界临床病例杂志》 2019年第6期765-772,共8页
BACKGROUND Sinonasal undifferentiated carcinoma (SNUC) is a rare aggressive tumor that is often unresectable. Optimal treatment for patients with unresectable, locally advanced SNUC (LA-SNUC) has not been established,... BACKGROUND Sinonasal undifferentiated carcinoma (SNUC) is a rare aggressive tumor that is often unresectable. Optimal treatment for patients with unresectable, locally advanced SNUC (LA-SNUC) has not been established, and the patient outcome remains poor. We report two cases of unresectable LA-SNUC in which induction chemotherapy with docetaxel, cisplatin and fluorouracil (TPF) followed by radiotherapy with concurrent cisplatin (CCRT), a standard treatment option for locally advanced head and neck cancer, demonstrated promising outcomes. CASE SUMMARY A 39-year-old man presented with tearing and pain in the right eye. A biopsy of the tumor invading the sinonasal cavities, right orbit and cranial base confirmed the diagnosis of LA-SNUC. Induction TPF chemotherapy induced remarkable tumor shrinkage and rapidly improved the symptoms. He subsequently received CCRT and achieved complete remission of the disease. The other case is a 21-year-old man who presented with worsening vision. The unresectable tumor involving the nasal septum and cranial base was pathologically diagnosed as SNUC. TPF chemotherapy followed by CCRT yielded complete remission of the disease with preserved visual function. Both patients have been disease-free for 44 mo. CONCLUSION Induction TPF chemotherapy followed by CCRT may remarkably improve the outcomes in LA-SNUC patients. 展开更多
关键词 SINONASAL undifferentiated carcinoma CHEMOTHERAPY with docetaxel CISPLATIN and fluorouracil CHEMOTHERAPY DOCETAXEL CISPLATIN Fluorouracil INTENSITY-MODULATED radiotherapy Chemoradiotherapy Case REPORT
在线阅读 免费下载
Treatment Patterns and Mortality Risk among Elderly Patients with Metastatic Triple Negative Breast Cancer in the United States: An Observational Cohort Study Using SEER-Medicare Data 预览
8
作者 Sacha Satram-Hoang Preeti Bajaj +3 位作者 Alisha Stein Patricia Cortazar Faiyaz Momin Carolina Reyes 《癌症治疗(英文)》 2019年第2期117-133,共17页
Purpose: Triple negative breast cancer is more aggressive than other breast cancer subtypes and accounts for up to 20% of all breast cancers. Despite the poorer prognosis, there are no approved targeted treatments ava... Purpose: Triple negative breast cancer is more aggressive than other breast cancer subtypes and accounts for up to 20% of all breast cancers. Despite the poorer prognosis, there are no approved targeted treatments available and chemotherapy remains the only choice. We examined treatment patterns and outcomes among elderly metastatic triple-negative breast cancer (mTNBC) patients in routine clinical practice. Methods: Patients were identified from the linked SEER-Medicare database between 1/1/2001 and 12/31/2013 and included de novo Stage IV (n = 776) and patients with distant metastasis followed an initial diagnosis of Stage I - III disease (n = 1851). Kaplan-Meier analyses and time-varying Cox proportional hazards regression were used to assess overall survival (OS). Results: The mean age at metastatic diagnosis was 77.6 years and 1259 (48%) patients received chemotherapy. Compared to <70 year olds, ≥70 year olds had worse performance status, higher comorbidity burden, and were less likely to receive chemotherapy (45% vs. 66%). Patients treated with chemotherapy had increased OS compared to untreated patients, and the survival advantage was more pronounced in the -month longer unadjusted OS compared to the ≥70 cohort (log rank p < 0.0001). This finding was supported in the adjusted multivariate model which showed a 46% increased risk of death for untreated patients in the <70 year olds and a 17% increased risk of death for untreated patients in the ≥70 year olds (vs. treated). Conclusions: In this real-world analysis, 48% of elderly mTNBC patients did not receive chemotherapy and a greater proportion were untreated in the ≥70 year old cohort (55%). Although the survival benefits of chemotherapy were greater in the younger cohort, the benefits of treatment persisted in ≥70 year olds. These findings suggest opportunities exist to improve the clinical treatment of elderly mTNBC patients. 展开更多
关键词 TRIPLE Negative BREAST Cancer ELDERLY Patients Chemotherapy Survival
在线阅读 免费下载
乳腺癌化疗患者输液港相关血栓形成的影响因素 预览
9
作者 毛美芬 徐文亚 +4 位作者 高雪娟 顾迪 贺春华 陈华 华艳萍 《护理学杂志》 CSCD 北大核心 2019年第11期33-35,共3页
目的探讨化疗患者完全植入性静脉输液港相关血栓形成的影响因素,为临床输液港植入护理方案的制定提供参考。方法回顾性收集278例乳腺癌化疗患者输液港相关血栓形成相关因素及血栓观察结果情况,进行非条件多因素Logistic回归分析,探索血... 目的探讨化疗患者完全植入性静脉输液港相关血栓形成的影响因素,为临床输液港植入护理方案的制定提供参考。方法回顾性收集278例乳腺癌化疗患者输液港相关血栓形成相关因素及血栓观察结果情况,进行非条件多因素Logistic回归分析,探索血栓形成的危险因素。结果输液港相关血栓形成的发生率31.3%(n=87,其中无症状血栓27.3%,症状性血栓4.0%)。血液高凝状态、临床分期为Ⅰ期、接受高密度化疗(ddAC-ddT)及FAC-T化疗方案的患者输液港相关血栓形成的发生率较高,是其主要的危险因素(P<0.05,P<0.01)。结论乳腺癌化疗患者输液港相关血栓形成发生率较高,与患者血凝状态、肿瘤分期及化疗方案有关,临床上对高危患者应加强监测,以降低血栓形成发生率。 展开更多
关键词 乳腺癌 输液港 化疗 血栓形成 危险因素 血液高凝状态 化疗方案 肿瘤分期
在线阅读 下载PDF
Cost-Effectiveness Analysis of Neoadjuvant Chemotherapy with Zoledronic Acid for HER2-Negative Breast Cancer in Japan: The JONIE1 Study 预览
10
作者 Kyoko Nakazawa Shota Saito +3 位作者 Masayuki Nagahashi Akimitsu Yamada Akira Toyama Kouhei Akazawa 《健康(英文)》 2019年第8期1017-1027,共11页
Objective: Zoledronic acid (ZOL) is a nitrogen-containing bisphosphonate that induces osteoclast apoptosis and inhibits bone resorption. Adding ZOL to neoadjuvant chemotherapy has been shown to have potential anticanc... Objective: Zoledronic acid (ZOL) is a nitrogen-containing bisphosphonate that induces osteoclast apoptosis and inhibits bone resorption. Adding ZOL to neoadjuvant chemotherapy has been shown to have potential anticancer benefits in women with HER2-negative breast cancer. The objective of the present study was to investigate ZOL’s cost-effectiveness from the perspective of health care payers in Japan. Methods: A Markov model was developed to evaluate the costs and effectiveness associated with ZOL + chemotherapy (CTZ) and chemotherapy (CT) alone over a 10-year time horizon. Monthly transition probabilities were estimated according to JONIE1 (Japan Organization of Neoadjuvant Innovative Expert) Study data and an extrapolated Weibull model. Health outcomes were measured in quality-adjusted life years (QALYs). Costs were calculated using year-2018 Japanese yen (JPY) (1.00 US dollars (USD) = 110.4 JPY). Model robustness was addressed through one-way and probabilistic sensitivity analysis. The costs and QALYs were discounted at a rate of 2% per year. Results: In the base case, the use of CTZ was associated with a gain of 3.94 QALYs. The incremental cost per QALY of the CTZ gain was 681,056.1 JPY (6168.99 USD) per QALY. Conclusion: It is convincing that neoadjuvant CTZ for patients with breast cancer would be expected to have statistically significant clinical efficacy. Addition of ZOL to CT might be a cost-effective option compared with CT alone. 展开更多
关键词 COST-EFFECTIVENESS INCREMENTAL COST-EFFECTIVENESS Ratio (ICER) Quality-Adjusted Life Year (QALY) Chemotherapy HER2-Negative BREAST Cancer
在线阅读 免费下载
宫颈癌化疗策略及进展
11
作者 王黎明 汪辉 《中国实用妇科与产科杂志》 CAS CSCD 北大核心 2019年第10期1095-1098,共4页
随着治疗手段的不断发展,宫颈癌的治疗效果较前明显提高。目前宫颈癌的治疗仍采用手术和放疗为主、化疗为辅的综合治疗方案。对于年轻的宫颈癌患者,放疗会损伤卵巢功能,可能导致一系列更年期症状,并且还会导致一系列并发症,严重影响患... 随着治疗手段的不断发展,宫颈癌的治疗效果较前明显提高。目前宫颈癌的治疗仍采用手术和放疗为主、化疗为辅的综合治疗方案。对于年轻的宫颈癌患者,放疗会损伤卵巢功能,可能导致一系列更年期症状,并且还会导致一系列并发症,严重影响患者生活质量。宫颈癌的化学治疗尤其是手术前后的辅助化疗越来越受到重视。因此,文章就宫颈癌术后辅助化疗以及术前新辅助化疗的最新进展及治疗策略做一大致总结。 展开更多
关键词 子宫颈肿瘤 化学治疗 新辅助化疗
香砂六君子汤加减辅助治疗减轻乳腺癌化疗患者化疗相关不良反应效果观察 预览
12
作者 吴彦岚 曾伟杰 《内科》 2019年第2期180-183,共4页
目的探讨香砂六君子汤加减辅助治疗对乳腺癌化疗患者化疗相关不良反应的影响。方法选取2017年1月至2018年12月我院收治的乳腺癌患者80例为研究对象,分为观察组与对照组,每组40例。对照组患者在化疗期间给予托烷司琼治疗,观察组患者在对... 目的探讨香砂六君子汤加减辅助治疗对乳腺癌化疗患者化疗相关不良反应的影响。方法选取2017年1月至2018年12月我院收治的乳腺癌患者80例为研究对象,分为观察组与对照组,每组40例。对照组患者在化疗期间给予托烷司琼治疗,观察组患者在对照组治疗基础上加用香砂六君子汤加减治疗。比较两组患者化疗期间的毒副反应及严重程度;比较化疗前后两组患者的生活质量(躯体状况、社会/家庭状况、情感状况、功能状况、附加关注)评分。结果观察组患者化疗期间恶心呕吐、白细胞计数下降的严重程度明显轻于对照组,差异有统计学意义(P<0.05)。化疗第10天,两组患者的躯体状况、社会/家庭状况、情感状况评分均显著提高,观察组患者这三个维度的评分均显著高于对照组,差异有统计学意义(P<0.05)。结论香砂六君子汤加减辅助治疗可显著减轻乳腺癌化疗患者化疗期间的毒副反应,明显提高患者的生活质量,具有较高的临床应用价值。 展开更多
关键词 乳腺癌 化疗 化疗相关不良反应 香砂六君子汤
在线阅读 下载PDF
参附注射液防治奥沙利铂、紫杉醇化疗所致外周神经毒性回顾性研究
13
作者 宋婷婷 熊绍权 +5 位作者 陈盼 李亚玲 邹晓玲 蔡蕊 罗秋月 王莉娟 《中国中西医结合杂志》 CAS CSCD 北大核心 2019年第1期28-32,共5页
目的观察参附注射液防治奥沙利铂、紫杉醇化疗外周神经毒性(CIPN)的作用并探讨其机制。方法回顾性分析2016年6月-2017年6月79例癌症患者资料,按治疗方法分为两组,对照组42例,予含奥沙利铂或紫杉醇方案化疗,试验组37例,化疗同期加用参附... 目的观察参附注射液防治奥沙利铂、紫杉醇化疗外周神经毒性(CIPN)的作用并探讨其机制。方法回顾性分析2016年6月-2017年6月79例癌症患者资料,按治疗方法分为两组,对照组42例,予含奥沙利铂或紫杉醇方案化疗,试验组37例,化疗同期加用参附注射液,共化疗4周期。化疗前及第2、4周期后评估CIPN,检测血清神经生长因子(NGF)含量。结果化疗2、4周期后,试验组CIPN总发生率[2周期:24.32%(9/37),4周期:32.43%(12/37)]均低于对照组[2周期:54.76%(23/42),4周期:66.66%(28/42);P<0.01];其中试验组紫杉醇CIPN发生率均低于对照组(P<0.05);两组奥沙利铂CIPN发生率差异无统计学意义(P>0.05);试验组NGF高于对照组(P<0.01)。结论参附注射液可减轻紫杉醇和奥沙利铂所致CIPN,其作用机制可能与促进血清NGF生长有关。 展开更多
关键词 参附注射液 化疗 奥沙利铂 紫杉醇 外周神经毒性 神经生长因子
Gestational Trophoblastic Diseases: A Review of the Clinical Presentation and Management at the Alex Ekwueme Federal University Teaching Hospital Abakaliki 预览
14
作者 Nwafor Johnbosco Ifunanya Obi Vitus Okwuchukwu +4 位作者 Ibo Chukwunenye Chukwu Obi Chuka Nobert Onwe Blessing Ugoji Darlington-Peter Chibuzor Onuchukwu Victor Uchenna 《临床医学病理报告(英文)》 2019年第6期164-171,共8页
Background: Gestational trophoblastic diseases (GTD) are potentially curable with retention of reproductive function once the correct diagnosis is made and treatment is commenced early with adequate follow up. Objecti... Background: Gestational trophoblastic diseases (GTD) are potentially curable with retention of reproductive function once the correct diagnosis is made and treatment is commenced early with adequate follow up. Objective: The objective of this study was to determine the incidence, clinical presentation, management and treatment outcomes of gestational trophoblastic diseases in a tertiary hospital in Abakaliki, South-east Nigeria. Materials and Methods: This was a retrospective descriptive study of gestational trophoblastic diseases managed at Alex Ekwueme Federal University Teaching Hospital, Abakaliki (AEFUTHA) over a 6-year period. The statistical analysis was done using SPSS version 22. Results: The incidence of GTD was 4.6 per 1000 deliveries. Women who were less than 20 years and more than 40 years of age accounted for 5.9% and 23.5% of cases of GTD respectively. Women who were para 5 and above accounted for 76.5% of those who presented with GTD. All the patients presented with vaginal bleeding. Suction evacuation (76.5%) was the commonest form of treatment offered to women with GTD. The commonest complication was anaemia (94.1%). Maternal death due to GTD was 8.8%. Most (58.8%) of the patients did not turn up for follow-up. Conclusion: Gestational trophoblastic diseases has remained an important cause of maternal morbidity and mortality in our hospital due to poor compliance with follow-up. Call and recall system should be introduced in the management of patients with GTD to improve compliance to management standard. 展开更多
关键词 GESTATIONAL MATERNAL MORTALITY CHEMOTHERAPY FOLLOW-UP
在线阅读 免费下载
肿瘤患者化疗辅助用药分析 预览
15
作者 刘国强 唐毅恒 《中国处方药》 2019年第5期52-53,共2页
目的了解某院化疗辅助药物应用现状,促进临床合理用药。方法在2017年7月1日~2018年6月30日期间,临床药师从某院病案室抽取相关科室化疗患者的出院病历。每月抽取病历:肿瘤科10份、放疗科10份、普外科5份、胸外科2份、妇科2份、呼吸内科5... 目的了解某院化疗辅助药物应用现状,促进临床合理用药。方法在2017年7月1日~2018年6月30日期间,临床药师从某院病案室抽取相关科室化疗患者的出院病历。每月抽取病历:肿瘤科10份、放疗科10份、普外科5份、胸外科2份、妇科2份、呼吸内科5份,总计408份。进行化疗辅助药物的统计分析。结果临床药师点评化疗患者住院病历408份,各类化疗辅助药物的使用率排名依次为:止吐药、扶正祛邪类中成药、骨髓功能恢复药、保肝药、抗过敏药、心功能保护药。化疗辅助药物应用合理的病历有345份,应用不合理的病历有63份。化疗辅助药物应用不合理主要表现在用药时机不当、注射剂溶媒选用不当、药物用法用量不当、联合用药不当等方面。结论该院临床应用化疗辅助药物基本规范。该院临床医师重视化疗药物所致的不良反应。 展开更多
关键词 化疗 辅助药物 药物不良反应 合理用药
在线阅读 下载PDF
腹腔恶性肿瘤术后无腹腔积液状态下超声引导腹腔置管辅助灌注化疗临床分析
16
作者 杜忠实 唐丽娜 +3 位作者 沈友洪 吴周贵 黄伟钦 陈轶洁 《肿瘤研究与临床》 CAS 2019年第4期250-252,共3页
目的探讨腹腔恶性肿瘤术后无腹腔积液状态下超声引导经皮穿刺腹腔置管辅助灌注化疗的临床价值。方法回顾性分析福建省肿瘤医院2013年4月至2018年9月收治的146例腹腔恶性肿瘤术后患者,腹腔置管前超声探查腹腔未见游离性积液,应临床要求行... 目的探讨腹腔恶性肿瘤术后无腹腔积液状态下超声引导经皮穿刺腹腔置管辅助灌注化疗的临床价值。方法回顾性分析福建省肿瘤医院2013年4月至2018年9月收治的146例腹腔恶性肿瘤术后患者,腹腔置管前超声探查腹腔未见游离性积液,应临床要求行279例次超声引导下经皮穿刺腹腔置管辅助灌注化疗。结果277例次完成腹腔置管,置管成功率99.3%(277/279),其中单次穿刺置管成功率83.2%(232/279),2例次(0.7%,2/279)置管过程中发现腹膜粘连放弃置管。53例(36.3%,53/146)患者进行≥2次的穿刺置管。置管成功者均顺利完成腹腔灌注化疗,未出现肠道损伤及出血。结论无腹腔积液状态下超声引导经皮穿刺置管辅助灌注化疗安全、可靠、简便,准确性和成功率高;为常规腹腔积液状态下穿刺置管途径受限时提供了新的置管方式,具有较好的临床应用价值。 展开更多
关键词 化学疗法 局部灌注 腹腔灌注化疗 置管 超声
术后补充化疗对完整周期新辅助化疗后未获pCR的ⅡA~ⅢB期乳腺癌患者预后的影响 预览
17
作者 刘梅 张敏 只向成 《天津医药》 CAS 北大核心 2019年第4期409-413,共5页
目的探讨术后补充化疗对完整周期新辅助化疗后未获病理完全缓解(pCR)的ⅡA~ⅢB期乳腺癌患者预后的影响。方法回顾性分析行完整周期新辅助化疗后未获pCR的208例ⅡA~ⅢB期的乳腺癌患者,其中81例患者术后行补充化疗(补充化疗组),127例未行... 目的探讨术后补充化疗对完整周期新辅助化疗后未获病理完全缓解(pCR)的ⅡA~ⅢB期乳腺癌患者预后的影响。方法回顾性分析行完整周期新辅助化疗后未获pCR的208例ⅡA~ⅢB期的乳腺癌患者,其中81例患者术后行补充化疗(补充化疗组),127例未行补充化疗(未补充化疗组)。分析2组患者3年总生存率、3年无病生存率及影响复发转移的因素。结果中位随访时间40个月,全组无病生存率为76.9%(160/208),3年总生存率为88.9%(185/208)。补充化疗组较未补充化疗组无病生存率提高(87.7%vs.72.4%,P<0.05)。补充化疗组和未补充化疗组3年总生存率分别为94.2%和92.1%,差异无统计学意义(P>0.05)。单因素分析表明雌激素受体(ER)状态、孕激素受体(PR)状态、HER-2状态及术后补充化疗情况是无病生存的影响因素(P<0.05),多因素分析显示术后未补充化疗(HR=2.044,P=0.033)和HER-2阳性(HR=3.418,P<0.001)是影响患者无病生存不良预后的独立危险因素。结论术后补充化疗可提高完整周期新辅助化疗后未获pCR的ⅡA~ⅢB期乳腺癌患者的无病生存率,HER-2阳性患者的预后更差。 展开更多
关键词 乳腺肿瘤 化学疗法 辅助 预后 影响因素 补充化疗
在线阅读 下载PDF
合生元改善大肠癌患者术后化疗不良反应的临床随机对照研究 预览
18
作者 鲁贺磊 秦环龙 《上海预防医学》 CAS 2019年第10期799-802,共4页
【目的】观察合生元对大肠癌患者缓解术后化疗相关不良反应及增强化疗效果的作用。【方法】选取2017年6月到2018年9月在同济大学附属第十人民医院行XELOX方案(奥沙利铂+卡培他滨)化疗的大肠癌术后患者40例,随机分为干预组和对照组。干... 【目的】观察合生元对大肠癌患者缓解术后化疗相关不良反应及增强化疗效果的作用。【方法】选取2017年6月到2018年9月在同济大学附属第十人民医院行XELOX方案(奥沙利铂+卡培他滨)化疗的大肠癌术后患者40例,随机分为干预组和对照组。干预组口服合生元制剂2个月,对照组口服安慰剂2个月。在患者首次化疗前和干预2个月后进行临床随访并收集临床检验结果。【结果】干预组发生化疗相关性腹泻(CID)2例,对照组9例,差异有统计学意义(P=0.013)。临床随访结果显示,干预组发生食欲下降2例,发生恶心呕吐3例,对照组分别为17例和10例,组间差异有统计学意义(P<0.001,P=0.018)。在便秘、腹痛、骨髓抑制、肿瘤标志物升高和粪隐血方面,两组间差异均无统计学意义(P>0.05)。干预组患者前白蛋白、白蛋白、谷草转氨酶(AST)和CD4/CD8等4项指标检测结果均优于对照组(P分别为<0.001、0.006、0.035、0.043)。其他临床指标差异均无统计学意义(P>0.05)。治疗过程中,患者未出现与合生元相关不良反应。【结论】合生元有助于改善大肠癌患者术后化疗相关不良反应,能够提高化疗患者的生活质量。 展开更多
关键词 合生元 大肠癌 化学治疗 化疗相关性腹泻
在线阅读 下载PDF
Current status of adjuvant chemotherapy for gastric cancer 预览
19
作者 In-Hwan Kim 《世界胃肠肿瘤学杂志:英文版(电子版)》 CAS 2019年第9期679-685,共7页
Although radical gastrectomy is a standard treatment for advanced gastric cancer,recurrence remains high.After several large-scale controlled studies have shown the beneficial effects of adjuvant chemotherapy,that tre... Although radical gastrectomy is a standard treatment for advanced gastric cancer,recurrence remains high.After several large-scale controlled studies have shown the beneficial effects of adjuvant chemotherapy,that treatment emerged as a standard option for advanced gastric cancer after gastrectomy.However,various guidelines from different countries have suggested different adjuvant chemotherapies.Understanding the differences between guidelines is very important for investigating further therapeutic strategies.Fortunately,because there are many ongoing studies about new regimens for adjuvant treatment,it is expected that patients with gastric cancer after surgery will have better outcome. 展开更多
关键词 GASTRIC cancer ADJUVANT CHEMOTHERAPY PERIOPERATIVE CHEMOTHERAPY CHEMORADIOTHERAPY Guidelines
在线阅读 免费下载
术前吉西他滨联合顺铂辅助化疗对Ⅲ期非小细胞肺癌患者手术及预后的影响
20
作者 张霞 《中国实用乡村医生杂志》 2019年第1期66-68,共3页
目的 探讨对Ⅲ期非小细胞肺癌患者在术前行吉西他滨联合顺铂辅助化疗对其手术及预后的影响.方法 选取2015年1月—2016年6月大连市第五人民医院收治的72例Ⅲ期非小细胞肺癌患者,依据治疗方案的不同分为对照组和观察组各36例.对照组直接... 目的 探讨对Ⅲ期非小细胞肺癌患者在术前行吉西他滨联合顺铂辅助化疗对其手术及预后的影响.方法 选取2015年1月—2016年6月大连市第五人民医院收治的72例Ⅲ期非小细胞肺癌患者,依据治疗方案的不同分为对照组和观察组各36例.对照组直接行手术治疗,观察组在手术治疗前给予吉西他滨联合顺铂化疗.对比两组患者的手术切除率、术后并发症及术后2年生存情况.结果 观察组手术总切除率为91.7%,高于对照组的72.2%,差异具有统计学意义( χ2=4.599,P<0.05).观察组术后并发症发生率为16.7%,对照组为22.2%,差异无统计学意义( χ2=0.355,P>0.05).观察组术后2年生存率为55.6%,高于对照组的30.6%,差异有统计学意义(χ2=4.589,P<0.05).结论 Ⅲ期非小细胞肺癌患者在术前给予吉西他滨联合顺铂辅助化疗,能有效提高手术切除率和术后生存率,具有较好的临床应用价值. 展开更多
关键词 肺癌 非小细胞 术前 化疗 吉西他滨 顺铂 手术 预后
上一页 1 2 250 下一页 到第
使用帮助 返回顶部 意见反馈
新型冠状病毒肺炎防控与诊疗专栏